Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma

doi:10.19803/j.1672-8629.20230785

Abstract

Abstract: Objective To propose risk prevention and control strategies by sorting out Objective studies on hepatocellular carcinoma caused by aristolochic acid (AA). Methods The research progress of hepatocellular carcinoma caused by AA was briefly described. The scientific significance of the re-study of the correlation between AA and hepatocellular carcinoma was elucidated. The objectivity, authenticity, and systematic research content of the study on hepatocellular carcinoma caused by AA by our group were sorted out, and the prevention and control strategies of traditional Chinese medicines containing AA were proposed. Results and Conclusion The result clarified a lack of a correlation between AA and hepatocellular carcinoma. Risk prevention and control strategies for safe use of traditional Chinese medicines and preparations containing aristolochic acid were proposed including clarification of risk-benefit ratios, comprehensive analysis of pharmaceutical research data for regulatory decision-making; adoption of graded management measures for patients with different levels of risk; establishment of quality-control methods for safety and standards for limitations; and establishment of a new method for the scientific cognition and precise evaluation of the use of traditional Chinese medicines.

Key words: aristolochic acid, hepatocellular carcinoma, safety evaluation, risk prevention and control, quality control

CLC Number:

FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230785

https://www.zgywjj.com/EN/Y2024/V21/I1/20

References

[1] NG AWT, POON SL, HUANG MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers[J]. Sci Transl Med, 2017, 9(412): eaan6446.
[2] WANG JB, BAI ZF, XIAO XH.Letter to the editor: is aristolochic acid the major cause of liver cancer in China and Asia?[J]. Hepatology, 2020, 71(3): 1130.
[3] POON SL, PANG ST, MCPHERSON JR, et al.Genome-wide mutational signatures of aristolochic acid and its application as a screening tool[J]. Sci Transl Med, 2013, 5(197): 28-37.
[4] LETOUZÉ E, SHINDE J, RENAULT V, et al.Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis[J]. Nat Commun, 2017, 8(1): 1315.
[5] LU ZN, LUO Q, ZHAO LN, et al.The Mutational features of aristolochic acid-induced mouse and human liver cancers[J]. Hepatology, 2020, 71(3): 929-942.
[6] ZHAI W, LAI H, KAYA NA, et al. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study[J]. Natl Sci Rev, 2021, 9(3): nwab192.
[7] CANDIA J, BAYARSAIKHAN E, TANDON M, et al.The genomic landscape of Mongolian hepatocellular carcinoma[J]. Nat Commun, 2020, 11(1): 4383.
[8] CHEN CJ, YANG YH, LIN MH, et al.Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection[J]. Int J Cancer, 2018, 143(7): 1578-1587.
[9] CHEN CJ, YANG YH, LIN MH, et al.Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(11): 1876-1883.
[10] CHEN CJ, CHIU WC, TSENG YH, et al.Aristolochic acid and the risk of cancers in patients with type 2 diabetes: Nationwide population-based cohort study[J]. Phytomedicine, 2022, 99: 154023.
[11] XIE D, SHI J, ZHOU J, et al.Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective[J]. Clin Mol Hepatol, 2023, 29(2): 206-216.
[12] BOOT A, JIANG N, ROZEN SG.Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma[J]. Theranostics, 2020, 10(12): 5578-5580.
[13] LU H, LIANG Y, GUAN B, et al.Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma[J]. Theranostics, 2020, 10(10): 4323-4333.
[14] BAI ZF, WANG CY, WANG JB, et al.Research and reflection on the correlation between aristolochic acid and liver cancer[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology(世界科学技术中医药现代化), 2019, 21(7): 1275-1279.
[15] SU T, FANG ZE, GUO YM, et al. No incidence of liver cancer was observed in a retrospective study of patients with aristolochic acid nephropathy[J/OL]. Chin J Integr Med,(2023-11-09)[2023-12-21]. https://doi.org/10.1007/s11655-023-3560-0.
[16] YANG L, SU T, LI XM, et al.Aristolochic acid nephropathy: variation in presentation and prognosis[J]. Nephrol Dial Transplant, 2012, 27(1): 292-298.
[17] FANG ZE, GUO Y, WANG ZL, et al.Asari radix et rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: a retrospective cohort study[J]. Chin Herb Med, 2022, 14(3): 470-475.
[18] CHEN SZ, DONG YP, QI XM, et al.Aristolochic acids exposure was not the main cause of liver tumorigenesis in adulthood[J]. Acta Pharmaceutica Sinica B, 2022, 12(5): 2252-2267.
[19] FANG ZE, WANG CY, NIU M, et al.Integration of transcriptomic and metabolomic data to compare the hepatotoxicity of neonatal and adult mice exposed to aristolochic acid I[J]. Frontiers in Genetics, 2022, 13: 840961.
[20] XIAO XH, BAI ZF, WANG JB, et al.Safety evaluation and drug vigilance of traditional Chinese medicine[J]. Chinese Science Bulletin(科学通报), 2021, 66(Z1): 407-414.
[21] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene[J]. IARC Monogr Eval Carcinog Risks Hum, 2002, 82: 1-556.
[22] CHEN SZ,DONG YA,WEN W,et al.Controversy over the liver carcinogenicity of aristolochic acid and drug safety considerations[J]. Academic Journal of Second Military Medical University(海军军医大学学报), 2021, 42(1): 1-7.
[23] YUN KY, XU ZC, SONG JY.Traditional Chinese medicine containing aristolochic acids and their detection[J]. Scientia Sinica(Vitae)(中国科学生命科学), 2019, 49(3): 238-249.
[24] XIAO XH, ZHAO X, BAI ZF, et al.New outlook on safety of traditional Chinese medicine: concept and practice[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2023, 48(10): 2557-2564.
[25] SCHMEISER HH, NORTIER JL, SINGH R, et al.Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy[J]. Int J Cancer, 2014, 135: 502-507.
[26] QIAO M, LEI C, CHEN ZJ, et al.Analysis and thinking on the status quo of safety item information in the instructions of traditional Chinese patent medicines containing Asari Radix et Rhizoma and its extracts[J]. Chinese Journal of Pharmacoviglance(中国药物警戒), 2023, 20(12): 1401-1406.
[27] GUO N, ZHAO Y, SUN Y, et al.Research progress of aristolochic acids and their biomarkers[J]. Acta Pharmaceutica Sinica(药学学报), 2021, 56(4): 972-982.
[28] NIE LX, WANG XP, LI J, et al.Content analysis and risk assessment of aristolochic acids in Chinese medicinal materials(decoction pieces)[J]. Chinese Journal of Pharmacoviglance(中国药物警戒), 2023, 20(5): 553-559.
[29] WU YX, DING QY, LIU J, et al.Research progress on chemical components, pharmacology and quality control of houttuyniae herba[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2022, 42(1): 108-120.
[30] WANG JB, HE CR, BAI ZF, et al.Precision medicine-oriented safety assessment strategy for traditional Chinese medicines: disease-syndrome-based toxicology[J]. Acta Pharmaceutica Sinica(药学学报), 2016, 51(11): 1681-1688.